Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Kura Oncology Inc.
Sponsor

Kura Oncology Inc.

United States 12730 High Bluff Drive Suite 400, 92130-2079, United States

About the sponsor

Clinical research in relapsed and/or refractory acute myeloid leukemia and genetically defined AML subtypes, with emphasis on NPM1-mutated and KMT2A-rearranged disease.

  • Relapsed/Refractory AML
  • NPM1-mutated AML
  • KMT2A-rearranged AML
  • MEIS1-associated biology

Interest extends to menin inhibition and combination approaches in both newly diagnosed and previously treated myeloid malignancies.

About Specializations

Kura Oncology Inc. runs clinical trials in conditions such as Acute myeloid leukaemia, Acute myeloid leukaemia recurrent, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

2 clinical trials

Acute myeloid leukaemia

Recruiting

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

Acute myeloid leukaemia recurrent

Not recruiting

Study of Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ziftomenib
  • Sponsor:Kura Oncology Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.